https://www.selleckchem.com/products/LBH-589.html
669). In the pediatric cohort, FCT did not differin the two groups (median 30 vs 48h, p = 0.5 while PCT was longer in IVA + IVQ group (median 72 vs 48h, p = 0.002). Adverse events (AEs) in adults were more common in the combination treatment group (6/19, 31.58% vs 2/26,7.69%, p = 0.055). IVA + IVQ treatment did not show better outcomewith respect to IVA monotherapy. AEs were more frequent in the IVA + IVQ group compared to the monotherapy. Further studies are necessary to investigate whether IVA + IVQ could be an efficient strategy to
Like
Comment
Share
